Johnson & Johnson has entered a voluntary agreement with the U.S. government that will expand discounted access to its medicines for millions of American patients while also securing tariff exemptions for the company’s pharmaceutical products and reinforcing its long-term U.S. manufacturing investment plans. Announced on January 8, 2026, the arrangement responds to President Donald Trump’s calls for lower drug prices and greater affordability in the U.S. healthcare system.
Under the accord, Johnson & Johnson will offer significantly discounted prices on certain medicines to U.S. patients through TrumpRx.gov, a direct-to-patient platform intended to make drugs available at costs comparable to those in other high-income countries. The company will also provide U.S. Medicaid programs access to its medicines at prices aligned with those paid in other developed markets, aiming to reduce out-of-pocket spending and ease budget pressures on public payers.
In return, Johnson & Johnson’s pharmaceutical portfolio will receive exemptions from U.S. tariffs, and the company reiterated plans tied to a broader, multiyear U.S. investment program totaling about $55 billion. That plan includes at least two new manufacturing facilities in North Carolina and Pennsylvania, which are expected to support domestic production capacity, innovation initiatives and high-skilled jobs.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!